Regenerative Medicine and IRB Review in Littleton
- For an IRB-reviewed program, ask which board and protocol apply to your care and what participation involves.
- IRB review concerns human research protections and is distinct from FDA product approval.
- PRP, donor-derived MSCs and exosome products have different contents and evidence; one label cannot validate all three.
- BSC’s donor-derived MSCs come from donated umbilical cord/placental tissue; the clinic does not treat spine conditions.
- Ask for the exact product, applicable FDA pathway, consent documents and individualized cost before choosing a procedure.
Understanding the treatment and the oversight behind it can help you decide whether a regenerative-medicine option fits your needs. At your free Beyond Stem Cells consultation, discuss your goals, alternatives and what any research participation would involve.
What does IRB review mean for regenerative medicine in Littleton?
IRB review for regenerative medicine in Littleton concerns the protections in place when people take part in research. If an IRB-reviewed option is discussed at Beyond Stem Cells, understanding the specific program can help you decide whether participation fits your needs. Begin with your diagnosis and goals, then learn what treatment, visits and follow-up would be involved.
What does an Institutional Review Board do?
An Institutional Review Board, or IRB, reviews research involving people with attention to their rights and welfare. The FDA’s explanation of IRBs describes review of protocols and materials such as informed-consent documents. An IRB can approve research, require changes or disapprove it. That review is important, but it answers a different question from whether a product has FDA approval for a particular medical use.
For a patient, the practical question is specific: Which approved protocol, if any, covers the procedure I am being offered? The answer should connect the program to your proposed treatment, diagnosis, provider and location. It should also explain what happens at each visit and which aspects of your care belong to the research. Knowing these details helps you weigh participation alongside ordinary clinical care.
- Board identity: ask for the name of the IRB and a participant contact.
- Protocol identity: request the title, identifier and current version.
- Current status: ask what documentation confirms the approval remains applicable.
- Covered procedure: identify the products, indications and sites included.
- Participation: clarify whether you would be a research participant and what that entails.
Does oversight prove that the treatment works?
No. A protocol may study a question whose answer is uncertain. Research participation should not be presented as a guarantee of personal benefit. Ask which published evidence supports the proposed treatment and whether that evidence concerns the exact product, condition and route being recommended. Collecting outcomes is also different from demonstrating effectiveness in a suitable study.
The clinic’s medical-team page identifies Dr. Michael Iannotti, MD as supervising physician, board certified in Family Medicine. Confirm who would evaluate and treat you under any proposed protocol. A provider’s credentials and a protocol’s approval documents are complementary pieces of information; neither substitutes for the other.
Use your free consultation to discuss the program in the context of your own health, rather than feeling you must choose a treatment in advance. Take time to read the information, consider the practical commitment and talk with another clinician if helpful. Your decision can include participation, another option or postponing treatment until your questions have been answered.
A clear answer starts with an assessment.
Bring your questions. A consultation helps you understand which options fit your history and goals.
How is IRB review different from FDA approval of regenerative products?
IRB review and FDA approval of regenerative products serve different purposes: research oversight does not grant permission to market an unapproved product or establish that it is effective. Treat them as separate questions when comparing a proposed regenerative procedure. Neither a clinic’s research language nor a product’s tissue source completes that comparison.
What does product-specific review require?
Start with the exact name, manufacturer and contents of what would be administered. “Regenerative medicine” is a field, not a product specification. PRP is prepared from the patient’s blood; BSC’s donor-derived MSC source is donated umbilical cord/placental tissue; exosomes are a separate product category. Evidence for one preparation does not establish the performance of another.
The FDA’s consumer alert on stem cells and exosomes warns about misleading claims and states that there are no FDA-approved exosome products. Approval is specific to a product and its intended use, so ask how that distinction applies to the treatment you are considering. For your decision, ask whether the exact product and proposed use have an applicable approval or lawful investigational pathway.
What if the procedure is described as research?
A research label does not remove regulatory requirements. For a cell product requiring an Investigational New Drug application, ask for documentation of an effective IND and how the proposed use fits it. The FDA’s regenerative-medicine patient information explains the need for FDA oversight of investigational products and cautions that a trial listing or company registration is not proof of lawful marketing.
A ClinicalTrials.gov entry can help identify a study, but an entry alone does not establish that you are enrolled, that a particular clinic is an authorized site, or that the product is approved. Ask the provider to connect the paperwork to your actual proposed procedure. If that connection cannot be explained, take time to obtain an independent medical opinion.
Why does the diagnosis still matter?
The decision also depends on whether the procedure fits your condition, goals and practical needs. A joint-pain question and a hair-loss question require different evaluation and evidence. BSC’s knee-pain information and hair-restoration information address different service concerns. Discuss the evaluation and treatment choices for your own concern, including whether any research participation would be relevant and what alternatives are available.
Oversight tells you who reviews the research; evidence tells you what is known about the proposed treatment.
Editorial framing informed by FDA research-oversight and patient-information guidance; not a patient testimonial.
Ask about recognized alternatives, uncertainties and risks before considering a combination. “Advanced” does not mean established, and “non-surgical” does not mean harmless. The regulatory explanation should be understandable without expecting you to interpret technical documents alone. A clear answer names the product, its use, the relevant pathway and the remaining uncertainty instead of relying on a reassuring label.
What should I verify before choosing a regenerative-medicine program?
Choosing a regenerative-medicine program requires verifying how the proposed treatment addresses your problem, what participation involves and what you would pay. A free consultation at Beyond Stem Cells is an opportunity to gather that information. It does not commit you to a procedure or establish your eligibility before medical evaluation.
What should I bring and request?
Bring your diagnosis if you have one, relevant reports, medication list and details of prior treatment. Explain the daily change you hope to achieve. Then ask for a written proposal that connects that goal to the exact intervention and evidence. If the consultation identifies an unresolved diagnosis, further assessment or referral may be more useful than choosing a product immediately.
- Clinical fit: why this treatment, for this diagnosis, at this stage?
- Product and pathway: what is administered and what supports its lawful use?
- Oversight: which current protocol covers the proposed procedure, if any?
- Consent: which risks, alternatives and uncertainties would you be accepting?
- Follow-up: who is responsible if you have a concern or no meaningful improvement?
How should research participation be explained?
If research enrollment is proposed, ask how it differs from ordinary clinical care. Request the consent document and time to read it. The FDA’s IRB frequently asked questions discusses informed consent and research oversight. Clarify required visits, data collection, whom to contact about participant rights, and what happens if you withdraw. Consent should help you understand the choice rather than simply record a signature.
Ask whether any visits or procedures are solely for research and whether you would pay for them. Separate possible personal benefit from the study’s knowledge-gathering goal. You should also understand which symptoms require prompt medical attention and how concerns are reported. The exact process must come from the applicable protocol and treating team, not a generic website timeline.
What costs and scope should be clear?
Treatment pricing is individualized. Request an itemized quote covering the product, administration, evaluations and follow-up, along with any possible additional charges. Do not assume insurance coverage or financing terms. The payments page can inform a discussion, but the written proposal should establish your actual obligations. The $500 promotion is limited to FUE and joint regeneration; it is not a discount for every regenerative service.
Beyond Stem Cells does not treat spine conditions. Ask for an appropriate referral if back or neck symptoms are your concern. A service menu also cannot establish that every listed treatment is suitable for you or included under IRB review.
For a free consultation, call (833) 720-7836 or use the contact page. Visit 5912 S Cody St, Suite 201, Littleton, CO 80123, Tuesday–Saturday, 9 am–5 pm. This guide is educational and does not replace clinical advice. A personal evaluation is needed to determine suitability, and individual outcomes vary.
What does each kind of documentation establish?
| Item | What it addresses | What it does not establish |
|---|---|---|
| IRB approval | Review of a specific human-research protocol and participant protections | FDA product approval, proven benefit or coverage of every clinic service |
| FDA approval for a specific product/use | Agency review tied to an identified product and indication | Approval of unrelated products, uses or clinic-wide protocols |
| Effective IND, where required | An applicable pathway to conduct a specified investigational study | Marketing approval or a guaranteed treatment benefit |
| ClinicalTrials.gov listing | Information about a registered study | FDA approval, lawful marketing or your enrollment at an authorized site |
| Program description | An introduction to the clinic’s services and approach | Which specific protocol, treatment and participation requirements apply to your care |
What should you discuss at your consultation?
- You have a defined health concern and want to compare evidence and alternatives.
- You are willing to ask for the exact protocol and product before proceeding.
- You understand that investigational participation may not provide personal benefit.
- You can review consent, visits, risks and costs before committing.
- A spine concern is outside BSC’s treatment scope; unclear diagnoses may require another evaluation first.
Candidacy is determined through an individual clinical evaluation. An option described on this page may not be appropriate for your condition.
What happens next?
-
Define the problem
Bring relevant records and explain the change you want in daily function or hair coverage.
-
Identify the proposal
Request the exact product, procedure, responsible provider and alternatives.
-
Review the documents
Discuss the applicable IRB protocol, FDA pathway and consent information, including visits, participant responsibilities and contacts for questions.
-
Decide after clarification
Review individualized cost, risks and follow-up, and take time for another opinion if important questions remain unanswered.
What does regenerative medicine and irb oversight cost?
Ask about benefits, limitations, and alternatives.
The right choice depends on a diagnosis, realistic expectations, and a plan you understand.
Who supervises care at Beyond Stem Cells?
Dr. Michael Iannotti, MD
Dr. Michael Iannotti is the clinic’s supervising physician and is board certified in Family Medicine. The clinical team evaluates your health history, goals, and suitability before recommending a service.
A treatment decision starts with understanding the problem, the options, and the limits.
Frequently asked questions about regenerative medicine and irb oversight
Does IRB approval mean a treatment is FDA approved?
No. IRB review addresses human-research protections within a specific protocol. FDA product approval and applicable investigational requirements are separate questions and must be verified for the exact proposed product and use.
What information should I receive about an IRB-reviewed program?
Ask for the reviewing board’s name, the protocol title and identifier, the treatments it covers and the consent document. You should understand whether you would be a research participant, who is responsible for your care, the applicable FDA pathway and whom to contact with questions.
How much does regenerative medicine cost in Colorado?
There is no single price for regenerative medicine. At Beyond Stem Cells, consultation is free and pricing depends on the specific proposed procedure or research arrangement. Request a written itemized quote, including any required follow-up or research-related charges.
Are PRP, MSCs and exosomes the same treatment?
No. PRP is prepared from your own blood. BSC’s donor-derived MSCs come from donated umbilical cord/placental tissue, while exosomes are a separate product category. Discuss the specific preparation, evidence and FDA status for the treatment being considered.
What should I ask Dr. Iannotti about the program?
Discuss how the treatment fits your diagnosis, its evidence and alternatives, and what any research participation would involve. Ask which board, protocol and FDA pathway apply. Dr. Michael Iannotti, MD is the supervising physician and is board certified in Family Medicine.
Explore related services and information.
Regenerative Medicine and IRB Oversight in Littleton, serving the Denver metro.
Beyond Stem Cells is located at 5912 S Cody St, Suite 201, Littleton, CO 80123. Our clinic serves patients from Littleton and surrounding Denver-area communities.
Hours: Tuesday–Saturday, 9:00am–5:00pm.
Get a plan that fits your situation.
Call the Littleton clinic or request your free consultation. Bring your questions about suitability, cost, and what to expect.
Where can you learn more?
- FDA: IRBs and human-subject protections
- FDA: IRB frequently asked questions, February 2025
- FDA: Regenerative-medicine patient information
- FDA: Stem-cell and exosome consumer alert
- Beyond Stem Cells: regenerative-program information
- BSC captured medical-team page
This page provides general educational information and is not individual medical advice. Treatments, risks, and suitability vary. Clinical and regulatory information should be discussed with a qualified clinician; no specific outcome is promised.